-
1
-
-
84890025521
-
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding
-
Tantry US, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
-
(2013)
J am Coll Cardiol
, vol.62
, pp. 2261-2273
-
-
Tantry, U.S.1
-
2
-
-
84888106006
-
Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality
-
Siller-Matula JM, et al. Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality. JACC Cardiovasc Interv 2013; 6: 1111-1128.
-
(2013)
JACC Cardiovasc Interv
, vol.6
, pp. 1111-1128
-
-
Siller-Matula, J.M.1
-
3
-
-
60949083948
-
Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
-
Sibbing D, et al. Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
-
(2009)
J am Coll Cardiol
, vol.53
, pp. 849-856
-
-
Sibbing, D.1
-
4
-
-
73949100670
-
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
-
Geisler T, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59-66.
-
(2010)
Eur Heart J
, vol.31
, pp. 59-66
-
-
Geisler, T.1
-
5
-
-
74749094606
-
Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay
-
Siller-Matula JM, et al. Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay. J Thromb Haemost 2010; 8: 351-359.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 351-359
-
-
Siller-Matula, J.M.1
-
6
-
-
34250020766
-
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
-
Buonamici P, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
-
(2007)
J am Coll Cardiol
, vol.49
, pp. 2312-2317
-
-
Buonamici, P.1
-
7
-
-
73449106079
-
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease
-
Migliorini A, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009; 120: 2214-2221.
-
(2009)
Circulation
, vol.120
, pp. 2214-2221
-
-
Migliorini, A.1
-
8
-
-
49349114160
-
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents
-
Gori AM, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
-
(2008)
J am Coll Cardiol
, vol.52
, pp. 734-739
-
-
Gori, A.M.1
-
9
-
-
70349510067
-
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients
-
Cuisset T, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 2009; 104: 1078-1082.
-
(2009)
Am J Cardiol
, vol.104
, pp. 1078-1082
-
-
Cuisset, T.1
-
10
-
-
8344221349
-
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
-
Matetzky S, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
-
(2004)
Circulation
, vol.109
, pp. 3171-3175
-
-
Matetzky, S.1
-
11
-
-
27644465874
-
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study
-
Gurbel PA, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
-
(2005)
J am Coll Cardiol
, vol.46
, pp. 1827-1832
-
-
Gurbel, P.A.1
-
12
-
-
33947495459
-
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes
-
Cuisset T, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-287.
-
(2007)
Thromb Haemost
, vol.97
, pp. 282-287
-
-
Cuisset, T.1
-
13
-
-
84886391924
-
Genetic variation of platelet function and pharmacology: An update of current knowledge
-
Geisler T, et al. Genetic variation of platelet function and pharmacology: An update of current knowledge. Thromb Haemost 2013; 110: 876-887.
-
(2013)
Thromb Haemost
, vol.110
, pp. 876-887
-
-
Geisler, T.1
-
14
-
-
56549090507
-
Platelet reactivity to adenosine diphosphate and long-term ischaemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target
-
Gurbel PA, et al. Platelet reactivity to adenosine diphosphate and long-term ischaemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008; 19: 595-604.
-
(2008)
Platelets
, vol.19
, pp. 595-604
-
-
Gurbel, P.A.1
-
15
-
-
84859181019
-
Phenotyping vs. Genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study
-
Siller-Matula JM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012; 10: 529-542.
-
(2012)
J Thromb Haemost
, vol.10
, pp. 529-542
-
-
Siller-Matula, J.M.1
-
16
-
-
33749503499
-
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
-
Geisler T, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
-
(2006)
Eur Heart J
, vol.27
, pp. 2420-2425
-
-
Geisler, T.1
-
17
-
-
33750479499
-
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
-
Hochholzer W, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
-
(2006)
J am Coll Cardiol
, vol.48
, pp. 1742-1750
-
-
Hochholzer, W.1
-
18
-
-
79960603731
-
High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes
-
Bonello L, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467-473.
-
(2011)
J am Coll Cardiol
, vol.58
, pp. 467-473
-
-
Bonello, L.1
-
19
-
-
67651173161
-
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. Clopidogrel in the TRITON-TIMI 38 trial
-
Michelson AD, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
-
(2009)
Eur Heart J
, vol.30
, pp. 1753-1763
-
-
Michelson, A.D.1
-
20
-
-
84866861394
-
Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at one year follow-up in patients receiving prasugrel
-
Bonello L, et al. Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at one year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
-
(2012)
J Thromb Haemost
, vol.10
, pp. 1999-2005
-
-
Bonello, L.1
-
21
-
-
80053630737
-
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel
-
Alexopoulos D, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011; 162: 733-739.
-
(2011)
Am Heart J
, vol.162
, pp. 733-739
-
-
Alexopoulos, D.1
-
22
-
-
82755162000
-
Antiplatelet Effects of Prasugrel vs Double Clopidogrel in Patients on Hemodialysis and High On-Treatment Platelet Reactivity
-
Alexopoulos D, et al. Antiplatelet Effects of Prasugrel vs Double Clopidogrel in Patients on Hemodialysis and High On-Treatment Platelet Reactivity. J Thromb Haemost 2011; 9: 2379-2385.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 2379-2385
-
-
Alexopoulos, D.1
-
23
-
-
84873530056
-
Randomised Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction
-
Alexopoulos D, et al. randomised Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
-
(2012)
Circ Cardiovasc Interv
, vol.5
, pp. 797-804
-
-
Alexopoulos, D.1
-
24
-
-
84875997213
-
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study
-
Parodi G, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.
-
(2013)
J am Coll Cardiol
, vol.61
, pp. 1601-1606
-
-
Parodi, G.1
-
25
-
-
74749097435
-
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
-
Sibbing D, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 250-256
-
-
Sibbing, D.1
-
26
-
-
77955603691
-
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window
-
Sibbing D, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-318.
-
(2010)
J am Coll Cardiol
, vol.56
, pp. 317-318
-
-
Sibbing, D.1
-
27
-
-
79958110089
-
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome
-
Campo G, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
-
(2011)
J am Coll Cardiol
, vol.57
, pp. 2474-2483
-
-
Campo, G.1
-
28
-
-
77955715900
-
Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention
-
Mokhtar OA, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 2010; 126: e147-149.
-
(2010)
Thromb Res
, vol.126
, pp. e147-e149
-
-
Mokhtar, O.A.1
-
29
-
-
84855852029
-
Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel
-
Parodi G, et al. Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel. Am J Cardiol 2012; 109: 214-218.
-
(2012)
Am J Cardiol
, vol.109
, pp. 214-218
-
-
Parodi, G.1
-
30
-
-
84882771753
-
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: The POBA study (predictor of bleedings with antiplatelet drugs)
-
Cuisset T, et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013; 6: 854-863.
-
(2013)
JACC Cardiovasc Interv
, vol.6
, pp. 854-863
-
-
Cuisset, T.1
-
31
-
-
65349185008
-
Antiplatelet therapy in diabetes: Efficacy and limitations of current treatment strategies and future directions
-
Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009; 32: 531-540.
-
(2009)
Diabetes Care
, vol.32
, pp. 531-540
-
-
Angiolillo, D.J.1
-
32
-
-
37549006004
-
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score
-
Geisler T, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 54-61
-
-
Geisler, T.1
-
33
-
-
80054919425
-
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis
-
Cayla G, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. J AmMed Assoc 2011; 306: 1765-1774.
-
(2011)
J Ammed Assoc
, vol.306
, pp. 1765-1774
-
-
Cayla, G.1
-
34
-
-
78651227746
-
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
-
Neubauer H, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011; 9: 3.
-
(2011)
BMC Med
, vol.9
-
-
Neubauer, H.1
-
35
-
-
79953296443
-
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention
-
Htun P, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 2011; 22: 627-633.
-
(2011)
J am Soc Nephrol
, vol.22
, pp. 627-633
-
-
Htun, P.1
-
36
-
-
77958466789
-
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease
-
Muller K, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010; 213: 256-262.
-
(2010)
Atherosclerosis
, vol.213
, pp. 256-262
-
-
Muller, K.1
-
37
-
-
54349121974
-
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
-
Siller-Matula JM, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
-
(2008)
J am Coll Cardiol
, vol.52
, pp. 1557-1563
-
-
Siller-Matula, J.M.1
-
38
-
-
77952048536
-
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
-
Harmsze AM, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
-
(2010)
Thromb Haemost
, vol.103
, pp. 920-925
-
-
Harmsze, A.M.1
-
39
-
-
77952591958
-
Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
-
Hochholzer W, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434.
-
(2010)
J am Coll Cardiol
, vol.55
, pp. 2427-2434
-
-
Hochholzer, W.1
-
40
-
-
80053419318
-
Combined influence of proton-pump inhibitors, calciumchannel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention
-
Harmsze AM, et al. Combined influence of proton-pump inhibitors, calciumchannel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost 2011; 9: 1892-1901.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 1892-1901
-
-
Harmsze, A.M.1
-
41
-
-
38349065084
-
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomised, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
-
Gilard M, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomised, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
-
(2008)
J am Coll Cardiol
, vol.51
, pp. 256-260
-
-
Gilard, M.1
-
42
-
-
70049098599
-
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomised study
-
Cuisset T, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomised study. J Am Coll Cardiol 2009; 54: 1149-1153.
-
(2009)
J am Coll Cardiol
, vol.54
, pp. 1149-1153
-
-
Cuisset, T.1
-
43
-
-
78349244351
-
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis
-
Siller-Matula JM, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 2624-2641.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 2624-2641
-
-
Siller-Matula, J.M.1
-
44
-
-
57149104093
-
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
-
Siller-Matula JM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-.e5.
-
(2009)
Am Heart J
, vol.157
, Issue.148
-
-
Siller-Matula, J.M.1
-
45
-
-
84859524326
-
Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor
-
Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 2012; 51: 305-318.
-
(2012)
Clin Pharmacokinet
, vol.51
, pp. 305-318
-
-
Teng, R.1
-
46
-
-
84891896681
-
Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors
-
Siller-Matula JM, et al. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost 2014; 12: 2-13.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 2-13
-
-
Siller-Matula, J.M.1
-
47
-
-
84896694643
-
Morphine decreases clopidogrel concentrations and effects: A randomised, double-blind, placebo-controlled trial
-
Hobl EL, et al. Morphine decreases clopidogrel concentrations and effects: a randomised, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63: 630-635.
-
(2014)
J am Coll Cardiol
, vol.63
, pp. 630-635
-
-
Hobl, E.L.1
-
48
-
-
82955240702
-
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
-
Hulot JS, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011; 4: 422-428.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, pp. 422-428
-
-
Hulot, J.S.1
-
49
-
-
61349191612
-
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis
-
Giusti B, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103: 806-811.
-
(2009)
Am J Cardiol
, vol.103
, pp. 806-811
-
-
Giusti, B.1
-
50
-
-
58249135635
-
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
-
Collet JP, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
-
(2009)
Lancet
, vol.373
, pp. 309-317
-
-
Collet, J.P.1
-
51
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega JL, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
-
(2009)
N Engl J Med
, vol.360
, pp. 354-362
-
-
Mega, J.L.1
-
52
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
Shuldiner AR, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
-
(2009)
J am Med Assoc
, vol.302
, pp. 849-857
-
-
Shuldiner, A.R.1
-
53
-
-
84863703442
-
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The CHARISMA genetics study
-
Bhatt DL, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 2012: 33: 2143-2150.
-
(2012)
Eur Heart J
, vol.33
, pp. 2143-2150
-
-
Bhatt, D.L.1
-
54
-
-
81855211733
-
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
-
Mega JL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc 2011; 306: 2221-2228.
-
(2011)
J am Med Assoc
, vol.306
, pp. 2221-2228
-
-
Mega, J.L.1
-
55
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
Simon T, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
-
(2009)
N Engl J Med
, vol.360
, pp. 363-375
-
-
Simon, T.1
-
56
-
-
77957792195
-
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: A case-control study
-
Harmsze AM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31: 3046-3053.
-
(2010)
Eur Heart J
, vol.31
, pp. 3046-3053
-
-
Harmsze, A.M.1
-
57
-
-
84862908606
-
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin
-
Jeong YH, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011; 4: 585-594.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, pp. 585-594
-
-
Jeong, Y.H.1
-
58
-
-
77958100874
-
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial
-
Wallentin L, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
-
(2010)
Lancet
, vol.376
, pp. 1320-1328
-
-
Wallentin, L.1
-
59
-
-
76349098199
-
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
-
Sibbing D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
-
(2010)
Circulation
, vol.121
, pp. 512-518
-
-
Sibbing, D.1
-
60
-
-
67949120411
-
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
-
Frere C, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009; 7: 1409-1411.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 1409-1411
-
-
Frere, C.1
-
61
-
-
77958105401
-
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis
-
Mega JL, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
-
(2010)
Lancet
, vol.376
, pp. 1312-1319
-
-
Mega, J.L.1
-
62
-
-
84860879920
-
No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting
-
S1-2
-
Jaitner J, et al. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv 2012; 5: 82-88, S1-2.
-
(2012)
Circ Cardiovasc Interv
, vol.5
, pp. 82-88
-
-
Jaitner, J.1
-
63
-
-
80053412474
-
Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention
-
Campo G, et al. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Thromb Haemost 2011; 9: 2106-2108.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 2106-2108
-
-
Campo, G.1
-
64
-
-
0042859862
-
Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
-
Fontana P, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-995.
-
(2003)
Circulation
, vol.108
, pp. 989-995
-
-
Fontana, P.1
-
65
-
-
66349133650
-
Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
-
Mega JL, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-2560.
-
(2009)
Circulation
, vol.119
, pp. 2553-2560
-
-
Mega, J.L.1
-
66
-
-
34248397644
-
A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
-
von Beckerath N, et al. A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819.
-
(2007)
Eur Heart J
, vol.28
, pp. 1814-1819
-
-
Von Beckerath, N.1
-
67
-
-
34948875324
-
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
-
Angiolillo DJ, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547.
-
(2007)
J am Coll Cardiol
, vol.50
, pp. 1541-1547
-
-
Angiolillo, D.J.1
-
68
-
-
38349137324
-
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomised study
-
Angiolillo DJ, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomised study. Thromb Haemost 2008; 99: 161-168.
-
(2008)
Thromb Haemost
, vol.99
, pp. 161-168
-
-
Angiolillo, D.J.1
-
69
-
-
58149476444
-
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
-
Bonello L, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
-
(2009)
Am J Cardiol
, vol.103
, pp. 5-10
-
-
Bonello, L.1
-
70
-
-
41249093357
-
Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomised prospective study
-
Bonello L, et al. Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomised prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
-
(2008)
J am Coll Cardiol
, vol.51
, pp. 1404-1411
-
-
Bonello, L.1
-
71
-
-
84883263516
-
Personalised antiplatelet treatment after percutaneous coronary intervention: The MADONNA study
-
Siller-Matula JM, et al. Personalised antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013; 167: 2018-2023.
-
(2013)
Int J Cardiol
, vol.167
, pp. 2018-2023
-
-
Siller-Matula, J.M.1
-
72
-
-
59049103979
-
Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement
-
Trenk D, et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement. EuroIntervention 2008; 4: 214-221.
-
(2008)
Eurointervention
, vol.4
, pp. 214-221
-
-
Trenk, D.1
-
73
-
-
57549090390
-
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: Results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomised study
-
Aleil B, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomised study. JACC Cardiovasc Interv 2008; 1: 631-638.
-
(2008)
JACC Cardiovasc Interv
, vol.1
, pp. 631-638
-
-
Aleil, B.1
-
74
-
-
62549101321
-
Randomised comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomised study
-
Jeong YH, et al. randomised comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomised study. J Am Coll Cardiol 2009; 53: 1101-1109.
-
(2009)
J am Coll Cardiol
, vol.53
, pp. 1101-1109
-
-
Jeong, Y.H.1
-
75
-
-
79955116606
-
High doses of clopidogrel to overcome genetic resistance: The randomised crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
-
Collet JP, et al. High doses of clopidogrel to overcome genetic resistance: the randomised crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4: 392-402.
-
(2011)
JACC Cardiovasc Interv
, vol.4
, pp. 392-402
-
-
Collet, J.P.1
-
76
-
-
67650745975
-
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomised Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study
-
Valgimigli M, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomised Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119: 3215-3222.
-
(2009)
Circulation
, vol.119
, pp. 3215-3222
-
-
Valgimigli, M.1
-
77
-
-
57549099501
-
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomised study
-
Cuisset T, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomised study. JACC Cardiovasc Interv 2008; 1: 649-653.
-
(2008)
JACC Cardiovasc Interv
, vol.1
, pp. 649-653
-
-
Cuisset, T.1
-
78
-
-
79952598836
-
Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomised trial
-
Price MJ, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomised trial. J Am Med Assoc 2011; 305: 1097-1105.
-
(2011)
J am Med Assoc
, vol.305
, pp. 1097-1105
-
-
Price, M.J.1
-
79
-
-
84861857758
-
A randomised trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGERPCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study
-
Trenk D, et al. A randomised trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGERPCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-2164.
-
(2012)
J am Coll Cardiol
, vol.59
, pp. 2159-2164
-
-
Trenk, D.1
-
80
-
-
84868332790
-
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularisation: The TRILOGY ACS platelet function substudy
-
Gurbel PA, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularisation: the TRILOGY ACS platelet function substudy. J Am Med Assoc 2012; 308: 1785-1794.
-
(2012)
J am Med Assoc
, vol.308
, pp. 1785-1794
-
-
Gurbel, P.A.1
-
81
-
-
84883281361
-
Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis
-
Aradi D, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2013; 167: 2140-2148.
-
(2013)
Int J Cardiol
, vol.167
, pp. 2140-2148
-
-
Aradi, D.1
-
82
-
-
84870032410
-
Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting
-
Collet JP, et al. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med 2012; 367: 2100-2109.
-
(2012)
N Engl J Med
, vol.367
, pp. 2100-2109
-
-
Collet, J.P.1
-
83
-
-
84877021553
-
A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after des implantation. Results from the ADAPT-DES study
-
Abstract LBCT
-
Stone G. A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after des implantation. Results from the ADAPT-DES study. J Am Coll Cardiol 2011; 58 (Supplement B): Abstract LBCT.
-
(2011)
J am Coll Cardiol
, vol.58
-
-
Stone, G.1
-
84
-
-
84870032410
-
Bedside monitoring to adjust antiplatelet therapy for coronary stenting
-
Collet JP, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
-
(2012)
N Engl J Med
, vol.367
, pp. 2100-2109
-
-
Collet, J.P.1
-
85
-
-
34250703278
-
Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection
-
Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5 (Suppl 1): 230-237.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 230-237
-
-
Cattaneo, M.1
-
86
-
-
84874759680
-
Hirudin anticoagulation allows more rapid determination of P2Y(1)(2) inhibition by the VerifyNow P2Y12 assay
-
Sumaya W, et al. Hirudin anticoagulation allows more rapid determination of P2Y(1)(2) inhibition by the VerifyNow P2Y12 assay. Thromb Haemost 2013; 109: 550-555.
-
(2013)
Thromb Haemost
, vol.109
, pp. 550-555
-
-
Sumaya, W.1
-
87
-
-
79951782413
-
Functional testing methods for the antiplatelet effects of aspirin
-
Schror K, et al. Functional testing methods for the antiplatelet effects of aspirin. Biomarkers Med 2011; 5: 31-42.
-
(2011)
Biomarkers Med
, vol.5
, pp. 31-42
-
-
Schror, K.1
-
88
-
-
0035469889
-
Differential inhibition of adenosine diphosphate-versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics
-
Weber AA, Schror K. Differential inhibition of adenosine diphosphate-versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood 2001; 98: 1619-1621.
-
(2001)
Blood
, vol.98
, pp. 1619-1621
-
-
Weber, A.A.1
Schror, K.2
-
89
-
-
84925376426
-
Clopidogrel Genotyping for Antiplatelet Guidance in MI Stenting: Maybe Reduced Ischaemic Risk
-
Nov. 6, 2013
-
Clopidogrel Genotyping for Antiplatelet Guidance in MI Stenting: Maybe Reduced Ischaemic Risk. Medscape 2013; Nov. 6, 2013.
-
(2013)
Medscape
-
-
-
90
-
-
79952435294
-
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
-
Gurbel PA, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 2011; 161: 598-604.
-
(2011)
Am Heart J
, vol.161
, pp. 598-604
-
-
Gurbel, P.A.1
-
91
-
-
84899713032
-
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: Impact of prasugrel and high-dose clopidogrel
-
Aradi D, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014; 63: 1061-1070.
-
(2014)
J am Coll Cardiol
, vol.63
, pp. 1061-1070
-
-
Aradi, D.1
-
92
-
-
84884870121
-
Why have studies of tailored anti-platelet therapy failed so far?
-
Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost 2013; 110: 628-631.
-
(2013)
Thromb Haemost
, vol.110
, pp. 628-631
-
-
Siller-Matula, J.M.1
Jilma, B.2
-
93
-
-
35549008493
-
Platelet function monitoring in patients with coronary artery disease
-
Gurbel PA, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
-
(2007)
J am Coll Cardiol
, vol.50
, pp. 1822-1834
-
-
Gurbel, P.A.1
-
94
-
-
84896701814
-
Lower Mortality Following Pulmonary Adverse Events and Sepsis with Ticagrelor Compared to Clopidogrel in the PLATO Study
-
Epub ahead of print
-
Storey RF, et al. Lower Mortality Following Pulmonary Adverse Events and Sepsis with Ticagrelor Compared to Clopidogrel in the PLATO Study. Platelets 2013; Epub ahead of print.
-
(2013)
Platelets
-
-
Storey, R.F.1
-
95
-
-
80455149677
-
Diurnal variation in platelet inhibition by clopidogrel
-
Kozinski M, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011; 22: 579-587.
-
(2011)
Platelets
, vol.22
, pp. 579-587
-
-
Kozinski, M.1
-
96
-
-
59849103903
-
Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report
-
Kozinski M, et al. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. Cardiol J 2008; 15: 530-536.
-
(2008)
Cardiol J
, vol.15
, pp. 530-536
-
-
Kozinski, M.1
-
97
-
-
63049117527
-
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
-
Siller-Matula JM, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res 2009; 123: 874-880.
-
(2009)
Thromb Res
, vol.123
, pp. 874-880
-
-
Siller-Matula, J.M.1
-
98
-
-
84874357792
-
Bedside monitoring of antiplatelet therapy for coronary stenting
-
De Caterina R, et al. Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med 2013; 368: 871.
-
(2013)
N Engl J Med
, vol.368
, pp. 871
-
-
De Caterina, R.1
-
99
-
-
84866368808
-
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (Updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
-
Jneid H, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-681.
-
(2012)
J am Coll Cardiol
, vol.60
, pp. 645-681
-
-
Jneid, H.1
-
100
-
-
84856158305
-
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
-
Hamm CW, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
-
(2011)
Eur Heart J
, vol.32
, pp. 2999-3054
-
-
Hamm, C.W.1
-
101
-
-
84855992555
-
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation?American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
-
Levine GN, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation?American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-122.
-
(2011)
J am Coll Cardiol
, vol.58
, pp. e44-e122
-
-
Levine, G.N.1
-
102
-
-
70149101223
-
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
-
102.Wallentin L, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045-1057.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
-
103
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
103.Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
-
(2007)
N Engl J Med
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
-
105
-
-
84894361062
-
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions
-
O’Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013; 82: E1-27.
-
(2013)
Catheter Cardiovasc Interv
, vol.82
, pp. E1-E27
-
-
O’Gara, P.T.1
-
106
-
-
84879663575
-
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes
-
Huber K, Lip GY. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thromb Haemost 2013; 110: 11-13.
-
(2013)
Thromb Haemost
, vol.110
, pp. 11-13
-
-
Huber, K.1
Lip, G.Y.2
-
107
-
-
33947328091
-
Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance
-
Siller-Matula J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
-
(2007)
Thromb Haemost
, vol.97
, pp. 385-393
-
-
Siller-Matula, J.1
-
108
-
-
82955203400
-
Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population
-
Alexopoulos D, et al. Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. J Thromb Thrombolysis 2011; 32: 328-333.
-
(2011)
J Thromb Thrombolysis
, vol.32
, pp. 328-333
-
-
Alexopoulos, D.1
-
109
-
-
55449137355
-
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
-
Geisler T, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9: 1251-1259.
-
(2008)
Pharmacogenomics
, vol.9
, pp. 1251-1259
-
-
Geisler, T.1
-
110
-
-
77249113768
-
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
-
Breet NJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
-
(2010)
J am Med Assoc
, vol.303
, pp. 754-762
-
-
Breet, N.J.1
-
111
-
-
79961046361
-
Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events
-
Freynhofer MK, et al. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011; 106: 230-239.
-
(2011)
Thromb Haemost
, vol.106
, pp. 230-239
-
-
Freynhofer, M.K.1
-
112
-
-
34447636769
-
Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
-
Bonello L, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 1630-1636
-
-
Bonello, L.1
-
113
-
-
77956654443
-
Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel
-
Bal Dit Sollier C, et al. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 2010; 104: 571-581.
-
(2010)
Thromb Haemost
, vol.104
, pp. 571-581
-
-
Bal Dit Sollier, C.1
-
114
-
-
84876130984
-
Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate(R) analyser
-
Johnston LR, et al. Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate(R) analyser. Platelets 2013; 24: 303-307.
-
(2013)
Platelets
, vol.24
, pp. 303-307
-
-
Johnston, L.R.1
-
115
-
-
82555161672
-
Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity
-
Capranzano P, et al. Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost 2011; 106: 1149-1157.
-
(2011)
Thromb Haemost
, vol.106
, pp. 1149-1157
-
-
Capranzano, P.1
-
116
-
-
84655161920
-
Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
-
Ferreiro JL, et al. Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. Rev Esp Cardiol 2011; 65: 105-106.
-
(2011)
Rev Esp Cardiol
, vol.65
, pp. 105-106
-
-
Ferreiro, J.L.1
-
117
-
-
84904607606
-
Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up
-
Epub ahead of print
-
Kozinski M, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J 2014; Epub ahead of print.
-
(2014)
Cardiol J
-
-
Kozinski, M.1
-
118
-
-
51749097093
-
Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction
-
Matetzky S, et al. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol 2008; 102: 524-529.
-
(2008)
Am J Cardiol
, vol.102
, pp. 524-529
-
-
Matetzky, S.1
-
119
-
-
73149118496
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: First experience in patients
-
Gurbel PA, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 2010; 8: 43-53.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 43-53
-
-
Gurbel, P.A.1
-
120
-
-
77950508416
-
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study
-
Gurbel PA, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
-
(2010)
Circulation
, vol.121
, pp. 1188-1199
-
-
Gurbel, P.A.1
-
121
-
-
38949133119
-
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification
-
Neubauer H, et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
-
(2008)
Thromb Haemost
, vol.99
, pp. 357-362
-
-
Neubauer, H.1
-
122
-
-
84860538806
-
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial
-
Roberts JD, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379: 1705-1711.
-
(2012)
Lancet
, vol.379
, pp. 1705-1711
-
-
Roberts, J.D.1
-
123
-
-
79955093619
-
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype
-
Kim IS, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011; 4: 381-391.
-
(2011)
JACC Cardiovasc Interv
, vol.4
, pp. 381-391
-
-
Kim, I.S.1
-
124
-
-
78650048685
-
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention
-
Hwang SJ, et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3: 450-459.
-
(2010)
Circ Cardiovasc Interv
, vol.3
, pp. 450-459
-
-
Hwang, S.J.1
-
125
-
-
0038649988
-
Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
-
Gurbel PA, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
-
(2003)
Circulation
, vol.107
, pp. 2908-2913
-
-
Gurbel, P.A.1
-
126
-
-
77949297362
-
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel
-
Bouman HJ, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482-488.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 482-488
-
-
Bouman, H.J.1
-
127
-
-
79956315296
-
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
-
Breet NJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011; 97: 983-990.
-
(2011)
Heart
, vol.97
, pp. 983-990
-
-
Breet, N.J.1
-
128
-
-
70449474088
-
The influence of clinical characteristics, laboratory and inflammatory markers on ’high on-treatment platelet reactivity’ as measured with different platelet function tests
-
Elsenberg EH, et al. The influence of clinical characteristics, laboratory and inflammatory markers on ’high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
-
(2009)
Thromb Haemost
, vol.102
, pp. 719-727
-
-
Elsenberg, E.H.1
-
129
-
-
35548957533
-
Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients
-
Gurbel PA, et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 121: 107-115.
-
(2007)
Thromb Res
, vol.121
, pp. 107-115
-
-
Gurbel, P.A.1
-
130
-
-
38349168418
-
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
-
Jakubowski JA, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-222.
-
(2008)
Thromb Haemost
, vol.99
, pp. 215-222
-
-
Jakubowski, J.A.1
-
131
-
-
77951644504
-
Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y
-
Linnemann B, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89: 597-605.
-
(2010)
Ann Hematol
, vol.89
, pp. 597-605
-
-
Linnemann, B.1
-
132
-
-
77955449383
-
Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients
-
Paniccia R, et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-292.
-
(2010)
Thromb Haemost
, vol.104
, pp. 287-292
-
-
Paniccia, R.1
-
133
-
-
38349090725
-
Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment
-
Sibbing D, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
-
(2008)
Thromb Haemost
, vol.99
, pp. 121-126
-
-
Sibbing, D.1
-
134
-
-
68649097104
-
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
-
Li YG, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 2009; 20: 316-327.
-
(2009)
Platelets
, vol.20
, pp. 316-327
-
-
Li, Y.G.1
-
135
-
-
84908512459
-
Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb
-
Epub ahead of print
-
Komosa A, et al. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb. Platelets 2014; Epub ahead of print.
-
(2014)
Platelets
-
-
Komosa, A.1
-
136
-
-
84879099050
-
Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin
-
Siller-Matula JM, et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2013; 167: 430-435.
-
(2013)
Int J Cardiol
, vol.167
, pp. 430-435
-
-
Siller-Matula, J.M.1
-
137
-
-
84881314865
-
Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy
-
Christ G, et al. Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy. Thromb Res 2013; 132: e36-e41.
-
(2013)
Thromb Res
, vol.132
, pp. e36-e41
-
-
Christ, G.1
-
138
-
-
84866789111
-
Effects of prasugrel on platelet inhibition during systemic endotoxaemia: A randomised controlled trial
-
Spiel AO, et al. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomised controlled trial. Clin Sci 2012; 123: 591-600.
-
(2012)
Clin Sci
, vol.123
, pp. 591-600
-
-
Spiel, A.O.1
-
139
-
-
84858690837
-
ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion
-
Siller-Matula JM, et al. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol 2012; 32: 902-909.
-
(2012)
Arterioscler Thromb Vasc Biol
, vol.32
, pp. 902-909
-
-
Siller-Matula, J.M.1
-
140
-
-
74249119049
-
Pantoprazole may enhance antiplatelet effect of entericcoated aspirin in patients with acute coronary syndrome
-
Kasprzak M, et al. Pantoprazole may enhance antiplatelet effect of entericcoated aspirin in patients with acute coronary syndrome. Cardiol J 2009; 16: 535-544.
-
(2009)
Cardiol J
, vol.16
, pp. 535-544
-
-
Kasprzak, M.1
-
141
-
-
74249104162
-
Clopidogrel response status assessed with Multiplate point-ofcare analysis and the incidence and timing of stent thrombosis over six months following coronary stenting
-
Sibbing D, et al. Clopidogrel response status assessed with Multiplate point-ofcare analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
-
(2010)
Thromb Haemost
, vol.103
, pp. 151-159
-
-
Sibbing, D.1
-
142
-
-
36949000480
-
The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis
-
Blindt R, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
-
(2007)
Thromb Haemost
, vol.98
, pp. 1329-1334
-
-
Blindt, R.1
-
143
-
-
29344466941
-
Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance
-
Lev EI, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
-
(2006)
J am Coll Cardiol
, vol.47
, pp. 27-33
-
-
Lev, E.I.1
-
144
-
-
34548722718
-
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-STsegment elevation acute coronary syndrome
-
Cuisset T, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-STsegment elevation acute coronary syndrome. Thromb Res 2007; 120: 893-899.
-
(2007)
Thromb Res
, vol.120
, pp. 893-899
-
-
Cuisset, T.1
-
145
-
-
79961114506
-
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44
-
Frelinger AL, 3rd, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226.
-
(2011)
Thromb Haemost
, vol.106
, pp. 219-226
-
-
Frelinger, A.L.1
-
146
-
-
44749084716
-
Relation of low response to clopidogrel assessed with point-ofcare assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris
-
Cuisset T, et al. Relation of low response to clopidogrel assessed with point-ofcare assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008; 101: 1700-1703.
-
(2008)
Am J Cardiol
, vol.101
, pp. 1700-1703
-
-
Cuisset, T.1
-
147
-
-
38949094987
-
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y(12) inhibition levels following prasugrel and clopidogrel administration
-
Jakubowski JA, et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y(12) inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
-
(2008)
Thromb Haemost
, vol.99
, pp. 409-415
-
-
Jakubowski, J.A.1
-
148
-
-
44949173754
-
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
-
Price MJ, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
-
(2008)
Eur Heart J
, vol.29
, pp. 992-1000
-
-
Price, M.J.1
-
149
-
-
77951679429
-
The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo
-
Mayr FB, et al. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 2010; 50: 1079-1087.
-
(2010)
Transfusion
, vol.50
, pp. 1079-1087
-
-
Mayr, F.B.1
-
150
-
-
70350464420
-
Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers
-
Siller-Matula JM, et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102: 397-403.
-
(2009)
Thromb Haemost
, vol.102
, pp. 397-403
-
-
Siller-Matula, J.M.1
-
151
-
-
33845765298
-
Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(Let) analyzer (Impact-R)
-
Panzer S, et al. Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R). Transfusion 2007; 47: 103-106.
-
(2007)
Transfusion
, vol.47
, pp. 103-106
-
-
Panzer, S.1
-
152
-
-
77955897278
-
Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans
-
Spiel AO, et al. Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans. Platelets 2010; 21: 464-469.
-
(2010)
Platelets
, vol.21
, pp. 464-469
-
-
Spiel, A.O.1
-
153
-
-
34547760330
-
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
-
Lordkipanidze M, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
-
(2007)
Eur Heart J
, vol.28
, pp. 1702-1708
-
-
Lordkipanidze, M.1
-
154
-
-
77953160638
-
A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease
-
Grove EL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
-
(2010)
Thromb Haemost
, vol.103
, pp. 1245-1253
-
-
Grove, E.L.1
-
155
-
-
73949093109
-
Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirintreated patients presenting for cardiac catheterisation
-
Frelinger AL, 3rd, et al. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirintreated patients presenting for cardiac catheterisation. Circulation 2009; 120: 2586-2596.
-
(2009)
Circulation
, vol.120
, pp. 2586-2596
-
-
Frelinger, A.L.1
-
156
-
-
27644536235
-
Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study
-
Gurbel PA, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
-
(2005)
J am Coll Cardiol
, vol.46
, pp. 1820-1826
-
-
Gurbel, P.A.1
-
157
-
-
33846837282
-
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?
-
Bliden KP, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
-
(2007)
J am Coll Cardiol
, vol.49
, pp. 657-666
-
-
Bliden, K.P.1
-
158
-
-
2342489360
-
A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation
-
Craft RM, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301-309.
-
(2004)
J Lab Clin Med
, vol.143
, pp. 301-309
-
-
Craft, R.M.1
-
159
-
-
61649091347
-
Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM
-
Scharbert G, et al. Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM. Platelets 2009; 20: 125-130.
-
(2009)
Platelets
, vol.20
, pp. 125-130
-
-
Scharbert, G.1
-
160
-
-
84860789698
-
Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: The timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study
-
Mahla E, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5: 261-269.
-
(2012)
Circ Cardiovasc Interv
, vol.5
, pp. 261-269
-
-
Mahla, E.1
|